Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Wee-1 kinase inhibitor AZD1775 · 1 trial · 1 indication
To assess the safety of AZD1775 following oral dosing of the capsule formulation in patients with advanced solid tumours
To assess the safety and tolerability of AZD1775 printed capsules following oral dosing in patients with advanced solid tumours. If new or aggravated physical findings imply deterioration compared with baseline, the finding will be reported as an Adverse Event, unless the findings are unequivocally due to disease progression.
To assess the safety and tolerability of AZD1775 printed capsules following oral dosing in patients with advanced solid tumours.
To assess the safety and tolerability of AZD1775 printed capsules following oral dosing in patients with advanced solid tumours.
To assess the safety and tolerability of AZD1775 printed capsules following oral dosing in patients with advanced solid tumours.
To assess the safety and tolerability of AZD1775 printed capsules following oral dosing in patients with advanced solid tumours; deterioration of haematology and clinical chemistry laboratory values as compared to baseline will be reported as Adverse Events if they fulfill any of the Serious Adverse Events criteria or are the reason for discontinuation of the study treatment unless clearly due to the progression of disease under study; if deterioration in a laboratory value is associated with clinical signs and symptoms, the sign or symptom will be reported as an AE and the associated laboratory result will be considered as additional information.
| Arm | Type | Description |
|---|---|---|
| Wee-1 kinase inhibitor AZD1775 | EXPERIMENTAL | To assess the safety of AZD1775 following oral dosing of the capsule formulation in patients with advanced solid tumours in patients who have previously completed 1 of the AZD1775 clinical pharmacology studies and not have met any requirements to permanently discontinue treatment with AZD1775. |
| Name | Type | Description |
|---|---|---|
| Wee-1 kinase inhibitor AZD1775 | DRUG | Patients will receive AZD1775 300 mg orally once daily. Days 1 to 5 and 8 to 12 of a 21 day cycle (ie, 5 days on and 2 days off for Weeks 1 and 2 of a 21-day cycle). All patients must receive a serotonin receptor 3 (5-HT3) antagonist, ondansetron (Zofran) 8 mg orally/IV or granisetron (Kytril) 1 mg orally/IV prior to each dose of AZD1775. Dexamethasone 4 mg orally/IV will be given with each AZD1775 dose at a minimum on the first day of dosing of AZD1775 of every 5 day dosing period, unless contraindicated or not well-tolerated. |
Inclusion Criteria: For inclusion in this study, patients must fulfil the following criteria: * Has read and understands the informed consent form (ICF) and has given written informed consent prior to any study procedures. * Female or male aged ≥18 years. * Has completed 1 of the parent AZD1775 cl...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
Wee-1 kinase inhibitor AZD1775 is an investigational small molecule being studied for the treatment of solid tumors. It is in Phase 1 clinical development and has not been approved by the FDA. The drug is being evaluated for safety and tolerability in patients with solid tumors.
Wee-1 kinase inhibitor AZD1775 targets the Wee-1 kinase, an enzyme involved in cell cycle regulation. By inhibiting this kinase, the drug may disrupt DNA damage repair processes in cancer cells. This mechanism is being explored as a potential therapeutic approach for solid tumors.
Wee-1 kinase inhibitor AZD1775 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. The drug is currently in Phase 1 clinical trials for the treatment of solid tumors.
Wee-1 kinase inhibitor AZD1775 is in Phase 1 clinical development. It is an investigational drug and has not received FDA approval. The ongoing clinical program is focused on assessing the safety and tolerability of the drug in patients with solid tumors.
Wee-1 kinase inhibitor AZD1775 has one completed clinical trial, NCT03313557, titled 'AZD1775 Continued Access Study to Assess Safety and Tolerability for Patients Enrolled in AZD1775 Clinical Pharmacology Studies.' This Phase 1 study enrolled 48 patients with solid tumors across the United States, France, Netherlands, and United Kingdom.
Yes, Wee-1 kinase inhibitor AZD1775 is also known as AZD1775. The drug is a small molecule being developed by AstraZeneca for the treatment of solid tumors. It is currently in Phase 1 clinical trials and remains an investigational agent.